PubRank

Neal Rosen

Author PubWeight™ 269.03‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006 18.44
2 RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010 17.31
3 BRAF mutation predicts sensitivity to MEK inhibition. Nature 2005 17.14
4 RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011 10.77
5 Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011 7.32
6 (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 2009 6.78
7 AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011 6.74
8 The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A 2010 6.54
9 Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 2007 5.44
10 The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005 4.48
11 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010 4.48
12 Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008 4.12
13 mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 2011 4.05
14 Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007 3.74
15 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002 3.72
16 Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002 3.70
17 Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 2010 3.54
18 Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012 3.37
19 Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003 3.32
20 Tumor adaptation and resistance to RAF inhibitors. Nat Med 2013 3.11
21 Mutant BRAF melanomas--dependence and resistance. Cancer Cell 2011 2.87
22 Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007 2.80
23 Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov 2014 2.79
24 An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell 2007 2.75
25 17AAG: low target binding affinity and potent cell activity--finding an explanation. Mol Cancer Ther 2003 2.74
26 Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008 2.71
27 Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004 2.66
28 Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 2013 2.65
29 Resistance to BRAF inhibition in melanomas. N Engl J Med 2011 2.58
30 Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007 2.50
31 BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2012 2.48
32 Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2012 2.47
33 HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011 2.43
34 Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002 2.34
35 Models from experiments: combinatorial drug perturbations of cancer cells. Mol Syst Biol 2008 2.33
36 Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 2006 2.24
37 Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 2012 2.19
38 Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A 2011 2.18
39 Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One 2007 2.14
40 Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003 2.04
41 mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med 2013 1.98
42 Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 2011 1.97
43 BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab 2008 1.95
44 Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 2008 1.94
45 Hsp90: a novel target for cancer therapy. Curr Top Med Chem 2006 1.93
46 Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res 2010 1.92
47 BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002 1.92
48 A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res 2003 1.83
49 Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A 2011 1.82
50 An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biol Ther 2010 1.77
51 PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 2010 1.77
52 Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 2008 1.74
53 A combinatorial strategy for treating KRAS-mutant lung cancer. Nature 2016 1.69
54 Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 2009 1.68
55 SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 2008 1.66
56 Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res 2014 1.55
57 Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res 2006 1.54
58 Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. Cancer Res 2002 1.53
59 HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther 2008 1.52
60 Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res 2012 1.50
61 Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov 2012 1.50
62 Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J Exp Med 2011 1.45
63 Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 2003 1.42
64 Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. Cancer Res 2011 1.40
65 Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem Biol 2004 1.38
66 Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 2005 1.36
67 The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res 2003 1.35
68 Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res 2013 1.34
69 Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nat Biotechnol 2008 1.33
70 BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 2014 1.32
71 A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 2008 1.31
72 Targeting HER2 in prostate cancer: where to next? J Clin Oncol 2007 1.29
73 Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. Cancer Discov 2014 1.25
74 Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002 1.16
75 Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol 2008 1.16
76 New efficient synthesis of resorcinylic macrolides via ynolides: establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target. J Am Chem Soc 2004 1.15
77 Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med 2015 1.15
78 Development of purine-scaffold small molecule inhibitors of Hsp90. Curr Cancer Drug Targets 2003 1.11
79 Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg Med Chem 2002 1.10
80 Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc Natl Acad Sci U S A 2003 1.07
81 Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus. Sci Signal 2012 1.06
82 A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2006 1.05
83 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res 2007 1.04
84 Development of a fluorescence polarization assay for the molecular chaperone Hsp90. J Biomol Screen 2004 1.03
85 Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern? J Clin Oncol 2011 1.03
86 RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer 2014 1.03
87 Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Res 2003 1.02
88 Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J Med Chem 2005 1.02
89 Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res 2009 0.97
90 Towards a unified model of RAF inhibitor resistance. Cancer Discov 2014 0.95
91 Synthesis of novel fluorescent probes for the molecular chaperone Hsp90. Bioorg Med Chem Lett 2003 0.95
92 Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol 2008 0.93
93 Total synthesis as a resource in the discovery of potentially valuable antitumor agents: cycloproparadicicol. Angew Chem Int Ed Engl 2003 0.92
94 PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma. Clin Cancer Res 2014 0.89
95 A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol 2011 0.89
96 Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition. Clin Cancer Res 2011 0.88
97 Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR. Chem Biol 2003 0.87
98 Targeted cancer therapies. Chin J Cancer 2011 0.86
99 ERK pathway inhibitors: how low should we go? Cancer Discov 2013 0.85
100 Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r. Magn Reson Med 2009 0.85
101 Oncogenic RAF: a brief history of time. Pigment Cell Melanoma Res 2010 0.84
102 Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer. Appl Immunohistochem Mol Morphol 2005 0.84
103 Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion. Proc Natl Acad Sci U S A 2011 0.83
104 Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor. Mol Cell Endocrinol 2007 0.82
105 The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer. Breast Cancer Res Treat 2002 0.81
106 Inhibition of mycobacterial infection by the tumor suppressor PTEN. J Biol Chem 2012 0.80
107 Monitoring the induction of heat shock factor 1/heat shock protein 70 expression following 17-allylamino-demethoxygeldanamycin treatment by positron emission tomography and optical reporter gene imaging. Mol Imaging 2012 0.78
108 Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. J Clin Invest 2016 0.77
109 Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. J Clin Invest 2016 0.76
110 General method for the synthesis of 8-arylsulfanyl adenine derivatives. J Org Chem 2004 0.76
111 Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urol 2004 0.75
112 Consensus statement: Expedition Inspiration fund for breast cancer research meeting 2002. Breast Cancer Res Treat 2003 0.75